This one-of-a-kind, interactive forum where top diligence leaders will discuss best practices and help you develop strategies for preparing for, conducting, and applying the results of the IP due diligence process.
Intellectual property is one of the most important assets a life sciences company has. As such, when engaging your team members in the buying, selling, licensing, distribution or franchising of IP, the need to engage in a meticulous and strategically timed IP due diligence review is essential to preventing a disappointing or even disastrous outcome.
ACI’s 6th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence which is essential to nearly every corporate transaction. Our esteemed speakers will provide insights on what to look for during the due diligence process, when to report findings, how to communicate effectively within and across teams, and when to adjust your expectations and decisions as the process proceeds.
2022 Agenda Highlights
- One Size Does Not Fit All: Tailoring Life Sciences IP Due Diligence to the Transaction
- Ownership and Inventorship 2.0: Common and Contemporary IP Due Diligence Landmines for Life Sciences Deals
- The Freedom to Operate Opinion: Practical Advice and Winning Strategies for Innovation and Negotiation
- Validity, Scope, and Enforceability: Determining the Breadth and Strength of Coverage
- Navigating the Complexities of Distressed Assets: Advanced Preparations in Times of Uncertainty
- A Special Three-Part Think Tank on Bridging the Gap Between the Business and IP Focusing on Market Approval, Valuation, and the Perspectives of Investors and Business Executive
SEE WHO ATTENDED IN THE PAST
- AMRI
- Akin Gump Strauss Hauer & Feld LLP
- Allergan plc
- Arnold & Porter Kaye Scholer LLP
- AtriCure Inc
- Axinn Veltrop & Harkrider LLP
- BA Ruskin Law LLC
- BONWRx
- Beck & Thomas
- Biogen
- Blaze Bioscience Inc
- Boehringer Ingelheim GmbH
- Boehringer Ingelheim International GmbH
- Brammer Bio
- Brinks Gilson & Lione
- Cantor Colburn LLP
- Carlson Caspers Vandenburgh Lindquist & Schuman PA
- Centre for Drug Research and Development
- Charles River Associates Inc
- Choate Hall & Stewart LLP
- Cipla Limited
- Clark & Elbing LLP
- Codiak BioSciences
- DRI Capital Inc
- Dentsply Sirona Inc
- Dr. Reddys Laboratories
- Drinker Biddle & Reath LLP
- Duane Morris LLP
- Eisai Inc
- Evolve BioSystems
- Finnegan Henderson Farabow Garrett & Dunner
- Fish & Richardson
- Fitzpatrick Cella Harper & Scinto
- Foghorn Therapeutics
- Forma Therapeutics Inc
- Futuragene
- Genentech Inc
- Gibson Dunn & Crutcher LLP
- Gilead Sciences
- Green Griffith & Borg-Breen LLP
- Heliae
- Hikma Pharmaceuticals USA Inc
- Houlihan Lokey
- Hueschen & Sage PLLC
- Immunogen Inc
- Indivior Inc
- Intellia Therapeutics Inc
- Ipsen Bioscience Inc
- Ironwood Pharmaceuticals Inc
- Jazz Pharmaceuticals
- Johnson-IP Strategy & Policy Consulting
- Jounce Therapeutics Inc
- KSQ Therapeutics Inc
- King & Spalding LLP
- Leason Ellis LLP
- MEDRx
- Marshall Gerstein & Borun LLP
- Mayer Brown LLP
- McDonnell Boehnen Hulbert & Berghoff LLP
- Merchant & Gould
- Merck & Co
- MicroVention Inc.
- Norris McLaughlin & Marcus P.A.
- Novartis
- Novartis Institutes For Biomedical Research
- Novartis Pharmaceuticals
- Obalon Therapeutics
- Ohlandt Greely Ruggiero & Perle LLP
- Paul Hastings LLP
- Pearne & Gordon LLP
- Pepper Hamilton LLP
- Pieris Pharmaceuticals Inc
- Porzio Bromberg & Newman P.C.
- Purdue Pharma LP
- Purdue Research Foundation
- Regeneron Pharmaceuticals Inc
- Roivant Sciences Inc
- Ropes & Gray LLP
- Rutgers Law School
- Sarepta Therapeutics
- Shire Pharmaceuticals
- SmartPharm Therapeutics
- Squire Patton Boggs Us LLP
- Steptoe & Johnson LLP
- Sterne Kessler Goldstein & Fox
- Sun Pharmaceutical Industries Ltd
- Taro Pharmaceutical Industries
- Teva Pharmaceuticals
- Transformative
- US Court of Appeals for Federal Circuit
- University of California
- VBI Vaccines Inc
- VLP Law Group LLP
- Wave Life Sciences
- Wilson Sonsini Goodrich & Rosati PC
Testimonials
Unique high level sessions, good mix of in-house and outside counsel.
Hearing from professionals involved in due diligence on a daily basis was very informative.
Great panels, lots of diversity of practice, and lots of seasoned practitioners.
The design of the event brought us all together along with room intimacy.
